SSGJ-707

• Description :

  SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer[1]

• UNSPSC :

  12352005

• Target :

  PD-1/PD-L1; VEGFR

• Related Pathways :

  Immunology/Inflammation; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  98.6

• Smiles :

  [SSGJ-707]

• Molecular Weight :

  (241.16 kDa)

• References & Citations :

  [1]Wu L, et al. A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC[J]. 2025.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported